Tianfeng Securities: Maintains a "buy" rating on Sino Biopharmaceutical (02696.HK) with a target price raised to 120.87 Hong Kong dollars.

According to the Wisdom Financial APP, TF Securities issued a research report stating that it will maintain a "buy" rating for WuXi Biologics (02696.HK). It is estimated that the company's overall revenue for the years 2025-2027 will be 5.873/5.970/7.125 billion yuan, with year-on-year growth rates of 2.60%/1.64%/19.36% respectively. The net profit attributable to the shareholders of the company is expected to be 827/7.97/11.22 billion yuan, with no changes from the previous forecast. Considering the further expansion of product advantages and indications for HLX43, the company's long-term profit forecast has been raised, with the target price increased from 78.01 Hong Kong dollars per share to 120.87 Hong Kong dollars per share.